Provided by Tiger Fintech (Singapore) Pte. Ltd.

ReShape Lifesciences, Inc.

0.3832
+0.073523.73%
Post-market: 0.41200.0288+7.52%18:25 EDT
Volume:151.54M
Turnover:65.68M
Market Cap:4.32M
PE:-0.03
High:0.4925
Open:0.4613
Low:0.3723
Close:0.3097
Loading ...
Apr 13, 2023

Major Issues Report

8-K - Current report
Mar 21, 2023

Major Issues Report

8-K - Current report
Mar 17, 2023

Beneficial Ownership Change

SC 13D - General statement of acquisition of beneficial ownership
Feb 15, 2023

Beneficial Ownership Change

SC 13D - General statement of acquisition of beneficial ownership
Feb 14, 2023

Beneficial Ownership Change

SC 13G/A [Amend] - Statement of acquisition of beneficial ownership by individuals
Feb 10, 2023

Major Issues Report

8-K - Current report
Feb 03, 2023

Correspondence

CORRESP [Cover] - Correspondence
Feb 03, 2023

Correspondence

CORRESP [Cover] - Correspondence
Feb 03, 2023

[Amend]Public Prospectus

S-1/A [Amend] - General form for registration of securities under the Securities Act of 1933
Feb 02, 2023

[Amend]Public Prospectus

S-1/A [Amend] - General form for registration of securities under the Securities Act of 1933
Feb 01, 2023

Correspondence

CORRESP [Cover] - Correspondence
Feb 01, 2023

Correspondence

CORRESP [Cover] - Correspondence
Jan 27, 2023

[Amend]Public Prospectus

S-1/A [Amend] - General form for registration of securities under the Securities Act of 1933
Jan 27, 2023

Major Issues Report

8-K - Current report
Jan 12, 2023

Public Prospectus

S-1 - General form for registration of securities under the Securities Act of 1933
Dec 28, 2022

Major Issues Report

8-K - Current report
Dec 20, 2022

Major Issues Report

8-K - Current report
Nov 14, 2022

Major Issues Report

8-K - Current report
Nov 14, 2022

Major Issues Report

8-K - Current report
Nov 14, 2022

Quarterly Report

10-Q - Quarterly report [Sections 13 or 15(d)]